MeSH term
Frequency | Condition_Probility | Humans | 171 | 0.0 |
Adult | 52 | 0.0 |
Aged | 39 | 0.0 |
Australia | 3 | 1.0 |
Biopsy | 2 | 0.0 |
Cohort Studies | 4 | 0.0 |
Ethnic Groups | 2 | 0.0 |
Female | 84 | 0.0 |
Ferritin/blood | 19 | 12.0 |
HLA Antigens/*genetics | 40 | 4.0 |
Heterozygote | 22 | 0.0 |
Histocompatibility Antigens Class I/*genetics | 68 | 20.0 |
Homozygote | 25 | 1.0 |
Iron/*metabolism | 25 | 19.0 |
Male | 92 | 0.0 |
*Membrane Proteins | 79 | 7.0 |
Middle Aged | 57 | 0.0 |
Mutation | 34 | 0.0 |
Prospective Studies | 3 | 0.0 |
Transferrin/metabolism | 24 | 14.0 |
Animals | 47 | 0.0 |
Gene Expression Regulation | 8 | 0.0 |
Genes, Recessive | 3 | 0.0 |
Hemochromatosis/*genetics | 44 | 44.0 |
Intestines/metabolism | 2 | 1.0 |
Iron/metabolism | 17 | 13.0 |
Research Support, Non-U.S. Gov't | 111 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 51 | 0.0 |
Aspartic Acid/genetics | 4 | 6.0 |
Case-Control Studies | 11 | 0.0 |
Cysteine/genetics | 7 | 5.0 |
European Continental Ancestry Group/genetics | 3 | 0.0 |
Genetic Predisposition to Disease | 8 | 0.0 |
Genotype | 43 | 0.0 |
Hemochromatosis/blood/ethnology/*genetics | 2 | 100.0 |
Histidine/genetics | 7 | 13.0 |
*Mutation | 24 | 0.0 |
Prevalence | 9 | 0.0 |
Questionnaires | 2 | 0.0 |
Tyrosine/genetics | 6 | 12.0 |
Histocompatibility Antigens Class I/genetics/*metabolism | 6 | 20.0 |
Iron/*metabolism/pharmacokinetics | 3 | 60.0 |
Membrane Proteins/genetics/*metabolism | 5 | 1.0 |
Mice | 35 | 0.0 |
Species Specificity | 2 | 0.0 |
Transfection | 7 | 0.0 |
Iron Overload/etiology/genetics | 2 | 100.0 |
Phenotype | 18 | 0.0 |
Hemochromatosis/*genetics/*metabolism | 6 | 85.0 |
Intestinal Absorption/*genetics | 3 | 75.0 |
Iron-Dextran Complex/pharmacology | 2 | 100.0 |
Liver/metabolism | 16 | 1.0 |
Membrane Proteins/*genetics | 26 | 3.0 |
Mice, Inbred C57BL | 9 | 0.0 |
Mice, Mutant Strains | 5 | 0.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 5 | 0.0 |
Gene Frequency | 27 | 0.0 |
Hemochromatosis/blood/diagnosis/*genetics | 2 | 100.0 |
Practice Guidelines | 2 | 2.0 |
Dose-Response Relationship, Drug | 2 | 0.0 |
Duodenum/*metabolism | 2 | 10.0 |
HLA Antigens/*genetics/physiology | 2 | 100.0 |
Histocompatibility Antigens Class I/*genetics/physiology | 2 | 66.0 |
Mice, Knockout | 24 | 0.0 |
Time Factors | 3 | 0.0 |
Tissue Distribution | 4 | 0.0 |
Transferrin/*metabolism | 3 | 5.0 |
Biological Transport | 6 | 0.0 |
Immunohistochemistry | 5 | 0.0 |
Receptors, Transferrin/metabolism | 7 | 10.0 |
France/epidemiology | 5 | 3.0 |
Iron/blood | 10 | 10.0 |
Polymorphism, Single Nucleotide | 2 | 0.0 |
RNA, Viral/blood | 2 | 0.0 |
Receptors, Transferrin/*genetics | 6 | 33.0 |
Aged, 80 and over | 11 | 0.0 |
Alleles | 22 | 0.0 |
Comparative Study | 12 | 0.0 |
Genes, MHC Class I | 11 | 8.0 |
Haplotypes | 5 | 0.0 |
*Polymorphism, Genetic | 7 | 0.0 |
Hepatitis C/*complications | 2 | 11.0 |
Risk Factors | 10 | 0.0 |
Smoking/epidemiology | 2 | 3.0 |
Diet | 2 | 0.0 |
HLA Antigens/genetics | 18 | 5.0 |
Hemoglobins/metabolism | 2 | 1.0 |
Histocompatibility Antigens Class I/genetics | 20 | 20.0 |
Homeostasis/genetics | 2 | 10.0 |
Intestinal Absorption | 6 | 4.0 |
Iron-Sulfur Proteins/metabolism | 3 | 60.0 |
DNA Mutational Analysis | 14 | 0.0 |
*Mutation, Missense | 3 | 0.0 |
*Point Mutation | 6 | 0.0 |
Absorption | 2 | 1.0 |
Homeostasis | 9 | 2.0 |
Iron/metabolism/*pharmacokinetics | 2 | 50.0 |
Iron Overload/genetics | 2 | 66.0 |
Chromosome Mapping | 4 | 0.0 |
Chromosomes, Human, Pair 6/*genetics | 4 | 2.0 |
Genetic Predisposition to Disease/*genetics | 3 | 0.0 |
Linkage (Genetics) | 2 | 0.0 |
Age Factors | 3 | 0.0 |
Age of Onset | 3 | 0.0 |
Logistic Models | 2 | 0.0 |
Polymerase Chain Reaction | 13 | 0.0 |
Polymorphism, Restriction Fragment Length | 6 | 0.0 |
Hemochromatosis/genetics | 17 | 48.0 |
Ferritin/*blood | 4 | 6.0 |
Reference Values | 4 | 0.0 |
Sex Factors | 3 | 0.0 |
Cation Transport Proteins/genetics | 2 | 12.0 |
Iron Overload/*genetics | 3 | 37.0 |
Membrane Proteins/genetics | 6 | 1.0 |
Molecular Sequence Data | 9 | 0.0 |
Polymorphism, Genetic | 4 | 0.0 |
Variation (Genetics) | 3 | 0.0 |
Cloning, Molecular | 4 | 0.0 |
Hela Cells | 8 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 3 | 0.0 |
Chromatography, High Pressure Liquid/methods | 2 | 1.0 |
Mutagenesis, Site-Directed | 2 | 0.0 |
Pedigree | 10 | 0.0 |
Adolescent | 10 | 0.0 |
DNA Primers | 8 | 0.0 |
Liver/pathology | 3 | 1.0 |
*Liver Transplantation | 2 | 1.0 |
Child | 4 | 0.0 |
Child, Preschool | 3 | 0.0 |
African Americans | 2 | 1.0 |
African Continental Ancestry Group/*genetics | 2 | 0.0 |
Mutation/genetics | 3 | 0.0 |
United States | 2 | 0.0 |
Hemochromatosis/complications/*genetics | 4 | 66.0 |
Electrophoresis, Agar Gel | 2 | 0.0 |
Mutation, Missense | 7 | 0.0 |
Point Mutation | 14 | 0.0 |
Polymerase Chain Reaction/methods | 4 | 0.0 |
Sensitivity and Specificity | 6 | 0.0 |
Gene Expression | 4 | 0.0 |
Hemochromatosis/genetics/metabolism | 3 | 75.0 |
Receptors, Transferrin/genetics | 3 | 27.0 |
Spleen/metabolism | 3 | 2.0 |
English Abstract | 12 | 0.0 |
Gene Frequency/genetics | 3 | 0.0 |
Heterozygote Detection | 8 | 1.0 |
Mutation/*genetics | 8 | 0.0 |
Binding Sites | 4 | 0.0 |
Ligands | 2 | 0.0 |
Hemochromatosis/epidemiology/*genetics | 6 | 46.0 |
Polymorphism, Genetic/genetics | 3 | 0.0 |
Italy | 5 | 0.0 |
Transferrin/analysis | 9 | 10.0 |
*Homozygote | 4 | 2.0 |
Retrospective Studies | 3 | 0.0 |
Sequence Analysis, DNA | 3 | 0.0 |
Statistics, Nonparametric | 2 | 0.0 |
Amino Acid Sequence | 7 | 0.0 |
Family Health | 7 | 0.0 |
Genetic Screening | 11 | 1.0 |
*Genotype | 2 | 0.0 |
Hungary/epidemiology | 2 | 9.0 |
Duodenum/metabolism | 5 | 13.0 |
HLA Antigens/*genetics/metabolism | 3 | 25.0 |
Histocompatibility Antigens Class I/*genetics/metabolism | 4 | 21.0 |
*Iron-Binding Proteins | 3 | 7.0 |
Liver/*metabolism | 7 | 1.0 |
*Ubiquitin-Conjugating Enzymes | 2 | 2.0 |
Genes, MHC Class I/*genetics | 5 | 6.0 |
HLA Antigens/blood/*genetics | 2 | 50.0 |
Hemochromatosis/blood/*diagnosis/genetics | 2 | 100.0 |
Histocompatibility Antigens Class I/blood/*genetics | 3 | 50.0 |
Iron Overload | 3 | 60.0 |
Aging | 2 | 0.0 |
Crosses, Genetic | 2 | 0.0 |
Mice, Inbred Strains | 2 | 0.0 |
Sex Characteristics | 4 | 0.0 |
Variation (Genetics)/*genetics | 2 | 0.0 |
Incidence | 3 | 0.0 |
Prognosis | 4 | 0.0 |
Biological Transport, Active | 2 | 1.0 |
Cell Membrane/metabolism | 2 | 0.0 |
*Genes, MHC Class I | 7 | 2.0 |
Kinetics | 5 | 0.0 |
Receptors, Transferrin/*metabolism | 4 | 17.0 |
Porphyria Cutanea Tarda/*genetics | 4 | 50.0 |
Histocompatibility Antigens Class I/genetics/metabolism | 3 | 42.0 |
Treatment Outcome | 3 | 0.0 |
Chromosomes, Human, Pair 6 | 2 | 1.0 |
*Cation Transport Proteins | 3 | 1.0 |
Cell Polarity | 2 | 1.0 |
Ferritin/metabolism | 4 | 13.0 |
Models, Biological | 3 | 0.0 |
Germany | 4 | 1.0 |
Hemochromatosis/diagnosis/*genetics | 3 | 42.0 |
Polymorphism, Genetic/*genetics | 4 | 0.0 |
Carcinoma, Hepatocellular/*genetics | 2 | 2.0 |
Liver Neoplasms/*genetics | 2 | 1.0 |
Odds Ratio | 2 | 0.0 |
Hemoglobins/analysis | 5 | 1.0 |
Iron Overload/blood/*genetics | 2 | 100.0 |
Caco-2 Cells | 2 | 0.0 |
Carrier Proteins/genetics | 2 | 0.0 |
Base Sequence | 7 | 0.0 |
Exons | 2 | 0.0 |
Introns | 2 | 0.0 |
Amino Acid Substitution | 11 | 0.0 |
Amino Acid Substitution/genetics | 3 | 1.0 |
Mutation, Missense/genetics | 2 | 1.0 |
Iron, Dietary/*metabolism | 2 | 66.0 |
Antibodies | 3 | 0.0 |
HLA Antigens/*genetics/immunology | 3 | 7.0 |
Histocompatibility Antigens Class I/*genetics/immunology | 2 | 7.0 |
Iron Overload/metabolism | 2 | 100.0 |
Hemochromatosis/metabolism | 2 | 66.0 |
Ethnic Groups/genetics | 2 | 1.0 |
Haplotypes/genetics | 3 | 0.0 |
Iron/blood/*metabolism | 4 | 44.0 |
Mass Screening | 3 | 1.0 |
Erythrocyte Indices | 2 | 3.0 |
Asparagine/genetics | 2 | 5.0 |
Models, Molecular | 2 | 0.0 |
Diagnosis, Differential | 3 | 0.0 |
Population Surveillance | 2 | 1.0 |
Alabama/epidemiology | 2 | 28.0 |
Exons/genetics | 2 | 0.0 |
Immunophenotyping | 2 | 0.0 |
Introns/genetics | 2 | 0.0 |
Down-Regulation | 2 | 0.0 |
HLA Antigens/*genetics/*metabolism | 2 | 50.0 |
Histocompatibility Antigens Class I/*genetics/*metabolism | 2 | 50.0 |
Iron-Regulatory Proteins | 4 | 44.0 |
Iron-Sulfur Proteins/genetics/*metabolism | 2 | 100.0 |
RNA-Binding Proteins/genetics/*metabolism | 2 | 3.0 |
Transferrin/genetics/*metabolism | 2 | 40.0 |
Doxycycline/pharmacology | 2 | 3.0 |
Gene Expression Regulation, Neoplastic | 3 | 0.0 |
HLA Antigens/*biosynthesis/genetics | 2 | 18.0 |
Histocompatibility Antigens Class I/*biosynthesis/genetics | 2 | 18.0 |
Iron/*deficiency | 4 | 25.0 |
Promoter Regions (Genetics) | 3 | 0.0 |
RNA-Binding Proteins/metabolism | 2 | 2.0 |
Regulatory Sequences, Nucleic Acid | 2 | 0.0 |
Hamsters | 2 | 0.0 |
Hydrogen-Ion Concentration | 3 | 0.0 |
HLA-A Antigens/genetics | 2 | 1.0 |
HLA-B Antigens/genetics | 2 | 0.0 |
*Major Histocompatibility Complex | 4 | 1.0 |
HLA Antigens/*metabolism | 2 | 6.0 |
Histocompatibility Antigens Class I/*metabolism | 3 | 3.0 |
Protein Binding | 2 | 0.0 |
Phlebotomy | 2 | 8.0 |
France | 2 | 0.0 |
*Genetic Screening | 2 | 1.0 |
Gene Expression Regulation/drug effects | 2 | 0.0 |
RNA, Messenger/analysis | 4 | 0.0 |
Hemochromatosis/*genetics/metabolism | 3 | 50.0 |
*Chromosomes, Human, Pair 6 | 3 | 1.0 |
Electrophoresis, Gel, Pulsed-Field | 2 | 0.0 |
Disease Models, Animal | 3 | 0.0 |
Iron Radioisotopes/diagnostic use | 2 | 22.0 |
Iron/*physiology | 2 | 33.0 |
Receptors, Transferrin/chemistry/*metabolism | 2 | 100.0 |
HLA Antigens/*genetics/*physiology | 2 | 50.0 |
Histocompatibility Antigens Class I/*genetics/*physiology | 2 | 50.0 |
Cross-Sectional Studies | 3 | 0.0 |
Follow-Up Studies | 2 | 0.0 |
Linkage Disequilibrium | 3 | 0.0 |
HLA-A Antigens/*genetics | 2 | 1.0 |
*Linkage Disequilibrium | 2 | 1.0 |
Hemochromatosis/blood/*genetics | 2 | 22.0 |
Histocompatibility Antigens Class I | 2 | 18.0 |
Mice, Transgenic | 2 | 0.0 |
Hemochromatosis/ethnology/*genetics | 2 | 66.0 |
Antimicrobial Cationic Peptides/*genetics | 2 | 66.0 |
Blotting, Western | 2 | 0.0 |
Rabbits | 2 | 0.0 |
Rats | 3 | 0.0 |
Rats, Wistar | 2 | 0.0 |
*Heterozygote | 3 | 0.0 |
Histocompatibility Antigens Class I/genetics/metabolism/*physiology | 2 | 100.0 |
Membrane Proteins/genetics/metabolism/*physiology | 2 | 13.0 |
Electrophoresis, Polyacrylamide Gel | 2 | 0.0 |
Cation Transport Proteins/metabolism | 2 | 20.0 |
Oxidative Stress | 2 | 0.0 |
